Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 18, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls related to certain Alaris™ Pump Modules Model 8100...
-
Jul 2, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2019 earnings conference call on Tuesday, August 6, 2019, at 8:00 a.m....
-
Jun 20, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory...
-
Jun 4, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the consideration payable in connection with its previously announced tender offers to purchase for cash, in the...
-
Jun 4, 2019Findings Based on Survey of 650 Health Care Professionals
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in...
-
Jun 3, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced tender offers to purchase for cash, in the order of priority...
-
May 31, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman Sachs 40th Annual Global Healthcare Conference on...
-
May 20, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the...
-
May 9, 2019- As reported, revenues of $4.195 billion decreased 0.6 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.195 billion for the second fiscal quarter ended March 31, 2019....
Apr 30, 2019New BD ChloraPrep™ Skin Preparation is the Only Commercially Available CHG Antiseptic Skin Preparation with Sterile Solution Designation in the U.S.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for BD ChloraPrep™...